CTLA4 and cancer: Consequently, therapeutic approaches such as HPV vaccines and immune checkpoint inhibitors (e.g., anti-CTLA4, PD-L1, and PD-L2 antibodies) are becoming increasingly vital in treating HPV-related cancers [25].